The global branded generics market size is expected to reach USD 410.86 billion by 2032, is expected to grow at a CAGR of 5.60 % during the forecast period.
Branded generics refer to off-patent drugs marketed under a company’s brand name. Unlike generic drugs, these are promoted similarly to patented products but are typically sold at a lower price point. Branded generics are essential in balancing cost efficiency with brand trust, especially in markets where healthcare costs are a significant concern.
𝐆𝐞𝐭 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.polarismarketresearch.com/industry-analysis/branded-generics-market/request-for-sample
Competitive Insight
Some of the major players operating in the global market include
- Teva Pharmaceutical,
- Lupin,
- Sanofi,
- Sun Pharmaceutical Industries,
- Reddy’s Laboratories,
- Endo International,
- GlaxoSmithKline,
- Pfizer,
- Apotex, and
- Viatris, Inc.
- Market’s Growth Drivers
2.1 Rising Demand for Affordable Medicines
The escalating costs of patented drugs have created a pressing need for more affordable alternatives. Branded generics provide an economical option for patients while maintaining the quality assurance of a known brand. This demand is particularly evident in developing economies, where healthcare affordability is a critical challenge.
2.2 Increasing Prevalence of Chronic Diseases
Chronic conditions such as diabetes, hypertension, and cardiovascular diseases are on the rise globally. These diseases often require long-term medication, making cost a significant factor. Branded generics offer a sustainable solution, ensuring that patients can adhere to treatment regimens without financial strain.
2.3 Expiration of Patents for Blockbuster Drugs
The expiration of patents for several high-revenue drugs has opened the market for branded generics. Pharmaceutical companies leverage this opportunity to introduce branded versions of these drugs, capitalizing on established therapeutic trust and reducing research and development costs.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:
The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.
Branded Generics Market, Drug Class Outlook (Revenue – USD Billion, 2019-2032)
- Alkylating Agents
- Antimetabolites
- Hormones
- Anti-Hypertensive
- Lipid Lowering Drugs
- Anti-Depressants
- Anti-Psychotics
- Anti-Epileptics
- Others
Branded Generics Market, Application Outlook (Revenue – USD Billion, 2019-2032)
- Oncology
- Cardiovascular Diseases
- Neurological Diseases
- Gastrointestinal Diseases
- Dermatological Diseases
- Acute and Chronic Pain
- Others
Branded Generics Market, Distribution Channel Outlook (Revenue – USD Billion, 2019-2032)
- Topical
- Oral
- Parenteral
- Others
- Key Trends in the Branded Generics Market
3.1 Surge in Emerging Market Participation
Emerging markets such as India, China, and Brazil are witnessing rapid adoption of branded generics. Factors such as expanding healthcare infrastructure, increasing government support, and a growing middle class have fueled this trend.
3.2 Strategic Partnerships and Collaborations
Pharmaceutical companies are increasingly entering strategic alliances to strengthen their market presence. Partnerships between local manufacturers and multinational corporations help in expanding geographical reach and optimizing production capabilities.
3.3 Technological Advancements in Drug Manufacturing
Innovations in manufacturing processes, including automation and quality control technologies, are enabling companies to produce high-quality branded generics more efficiently. These advancements are also helping manufacturers meet stringent regulatory standards across various regions.
- Research Scope and Opportunities
4.1 Focus Areas for Future Research
Future research in the branded generics market can explore improving bioequivalence studies, ensuring consistent drug quality, and addressing regulatory challenges in different markets. Additionally, understanding patient behavior and trust in branded generics can offer valuable insights for marketing strategies.
4.2 Potential Growth Opportunities
The increasing integration of digital tools, such as e-pharmacies and telemedicine, provides significant growth opportunities for the branded generics market. Companies can also focus on expanding their portfolio to cover therapeutic areas with unmet needs, ensuring robust market penetration.
Recent Developments
In March 2023, Viatris, Inc., Aurobindo Pharma, and Cipla Inc. received sublicenses from the United Nations-backed Medicines Patent Pool (MPP) to manufacture affordable branded generic versions of Apretude—a drug originally developed by GSK plc for HIV treatment.
More Trending Latest Reports By Polaris Market Research: